UB Paderborn / Katalog / Suche / in CDI

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

Nutrients, 2023-08, Vol.15 (16), p.3533

2023

Volltextzugriff (PDF)

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

Nutrients, 2021-11, Vol.13 (12), p.4295

2021

Volltextzugriff (PDF)

[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

EJNMMI research, 2019-08, Vol.9 (1), p.84-8, Article 84

2019

Volltextzugriff (PDF)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Frontiers in oncology, 2023-05, Vol.13, p.1151701-1151701

2023

Volltextzugriff (PDF)

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (23), p.6856-6864

2013

Volltextzugriff (PDF)

Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

The Journal of nuclear medicine (1978), 2023-07, Vol.64 (7), p.1030-1035

2023

Volltextzugriff (PDF)

Staging Prostate Cancer with 68 Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

Journal of Nuclear Medicine, 2023-07, Vol.64 (7), p.1030-1035

2023

Volltextzugriff (PDF)

The psychological impact of early prostate cancer: A prospective evaluation

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.210-210

2020

Volltextzugriff (PDF)

Geographic variation of decipher genomic classifier in patients with early prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.376-376

2023

Volltextzugriff (PDF)

P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.162-162

2023

Volltextzugriff (PDF)

Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement

European journal of nuclear medicine and molecular imaging, 2022-05, Vol.49 (6), p.2077-2085

2022

Volltextzugriff (PDF)

Cutaneous and subcutaneous metastases of rectal cancer

International journal of clinical oncology, 2004-06, Vol.9 (3), p.202-205

2004

Volltextzugriff (PDF)

Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4512-4512

2023

Volltextzugriff (PDF)

The association between allopurinol use and urologic malignancies: A nested case-control study

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.435-435

2020

Volltextzugriff (PDF)

Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16609-e16609

2019

Volltextzugriff (PDF)

68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Canadian Urological Association journal, 2022-07, Vol.16 (7), p.E381-E385

2022

Volltextzugriff (PDF)

Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a prospective phase II study

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.14-14

2018

Volltextzugriff (PDF)

Gci-prostcite-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Canadian Urological Association journal, 2022-07, Vol.16 (7), p.E381

2022

Volltextzugriff (PDF)

Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection

Prostate cancer and prostatic diseases, 2021-09, Vol.24 (3), p.910-916

2021

Volltextzugriff (PDF)

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Canadian Urological Association journal, 2022-02

2022

Volltextzugriff (PDF)

Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16588-e16588

2017

Volltextzugriff (PDF)

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.491-497

2019

Volltextzugriff (PDF)

Genomic analysis of urothelial cancer and associations with treatment choice and outcome

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16026-e16026

2019

Volltextzugriff (PDF)

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib

The oncologist (Dayton, Ohio), 2016-10, Vol.21 (10), p.1212-1217

2016

Volltextzugriff (PDF)

Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.282-282

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

Staging Prostate Cancer with 68 Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

The psychological impact of early prostate cancer: A prospective evaluation

Geographic variation of decipher genomic classifier in patients with early prostate cancer

P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study

Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement

Cutaneous and subcutaneous metastases of rectal cancer

Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials

The association between allopurinol use and urologic malignancies: A nested case-control study

Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study

68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a prospective phase II study

Gci-prostcite-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer

Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Genomic analysis of urothelial cancer and associations with treatment choice and outcome

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib

Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)

Suchergebnisse filtern